Ceftobiprole

Ceftobiprole
IUPAC name	(6R,7R)-7-[ [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Other names	BAL5788
Identifiers
3D model (JSmol)	Interactive image
ECHA InfoCard	Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
PubChem CID	6918430
SMILES C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=C5NSC(=N5)N)N=O)SC3)C(=O)O)C2=O
Properties
Chemical formula	C₂₀H₂₂N₈O₆S₂
Molar mass	534.56868
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ceftobiprole is an experimental cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus.^[1] It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development.^[2]

↑ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.
↑ Basilea.com